Heron shares surge on positive pain drug data

Shares of Redwood City, CA-based Heron Therapeutics shot up 20% on its release of positive data from its Phase II clinical study of HTX-011 for treating post-operative pain in patients undergoing bunionectomy. The biotech says that all primary and secondary endpoints were met in the study of their drug, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.